ATE17189T1 - 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe. - Google Patents

5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.

Info

Publication number
ATE17189T1
ATE17189T1 AT82902190T AT82902190T ATE17189T1 AT E17189 T1 ATE17189 T1 AT E17189T1 AT 82902190 T AT82902190 T AT 82902190T AT 82902190 T AT82902190 T AT 82902190T AT E17189 T1 ATE17189 T1 AT E17189T1
Authority
AT
Austria
Prior art keywords
oral dosage
dosage form
release oral
anionic polymer
intestinal juice
Prior art date
Application number
AT82902190T
Other languages
English (en)
Inventor
John Rhodes
Brian Kenneth Evans
Original Assignee
Tillott J B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10523624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE17189(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillott J B Ltd filed Critical Tillott J B Ltd
Application granted granted Critical
Publication of ATE17189T1 publication Critical patent/ATE17189T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT82902190T 1981-07-31 1982-07-28 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe. ATE17189T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8123573 1981-07-31
PCT/GB1982/000235 WO1983000435A1 (en) 1981-07-31 1982-07-28 Orally administrable pharmaceutical compositions
EP82902190A EP0097651B1 (de) 1981-07-31 1982-07-28 5-asa enthaltende orale verabreichungsform mit verzögerter wirkstofffreigabe

Publications (1)

Publication Number Publication Date
ATE17189T1 true ATE17189T1 (de) 1986-01-15

Family

ID=10523624

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82902190T ATE17189T1 (de) 1981-07-31 1982-07-28 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.

Country Status (14)

Country Link
US (2) US5541170A (de)
EP (1) EP0097651B1 (de)
JP (1) JPS58501174A (de)
AT (1) ATE17189T1 (de)
AU (1) AU551173B2 (de)
CA (1) CA1172570A (de)
DE (1) DE3268277D1 (de)
DK (1) DK158931C (de)
FI (1) FI85216C (de)
GB (1) GB2123695B (de)
IT (1) IT1149328B (de)
NO (1) NO159696C (de)
WO (1) WO1983000435A1 (de)
ZA (1) ZA825384B (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57500432A (de) * 1980-03-20 1982-03-11
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
GB2196252B (en) * 1986-09-18 1990-10-17 London Pharmacy Innovation Gastric controlled-release dosage forms
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JPH01299226A (ja) * 1988-05-27 1989-12-04 Seikagaku Kogyo Co Ltd サラゾスルファピリジン腸溶顆粒
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
EP0544671A4 (en) * 1990-04-18 1993-09-15 The University Of Utah Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling
NL9002336A (nl) * 1990-10-24 1992-05-18 Leuven K U Res & Dev Bekledings- of matrixmateriaal voor geneesmiddelen.
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
GEP19971086B (en) * 1991-02-22 1997-12-02 Tillotts Pharma Ag Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine
AU1587392A (en) * 1991-03-15 1992-10-21 Norwich Eaton Pharmaceuticals, Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
EP0667148B1 (de) * 1992-11-06 2002-07-03 Hisamitsu Pharmaceutical Co., Inc. Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
SE9401738D0 (sv) * 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB2303550B (en) * 1994-06-21 1998-07-08 Danbiosyst Uk Colonic drug delivery system
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US6156340A (en) * 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
AU2521797A (en) * 1996-04-12 1997-11-07 Japan Atomic Energy Research Institute Ph-sensitive polymers
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
EP1101490B1 (de) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
ATE293981T1 (de) * 1998-09-21 2005-05-15 Amato Pharm Prod Ltd System zur oralen wirkstoffabgabe zur steigerung der bioverfügbarkeit von aktiviertem glycyrrhetin
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6620834B1 (en) 1999-07-02 2003-09-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
RU2153340C1 (ru) * 1999-12-14 2000-07-27 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтический состав, регулирующий метаболические процессы, и способ его получения
US20030114349A1 (en) * 2000-04-27 2003-06-19 The Procter & Gamble Company Coating composition for solid bodies
BR0112393A (pt) 2000-06-21 2003-07-08 Internat Health Man Associates Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais
AU8531101A (en) 2000-08-29 2002-03-13 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
RU2187307C1 (ru) * 2001-10-15 2002-08-20 Сыров Кирилл Константинович Твердые стабильные лекарственные формы преднизолона
AR036797A1 (es) * 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
WO2004093883A2 (en) 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
WO2005021013A1 (ja) 2003-09-01 2005-03-10 Earthus, Inc. β−ヒドロキシ短〜中鎖脂肪酸重合体
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP1722630A4 (de) * 2004-01-20 2009-05-27 Richard F Harty Zusammensetzungen und verfahren zur behandlung von entzündungskrankheiten
EP2361620B1 (de) 2004-02-06 2016-04-06 PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
ES2565848T3 (es) 2004-07-07 2016-04-07 Biocon Limited Síntesis de compuestos inmunorreguladores unidos por grupos azoicos
KR20080085924A (ko) * 2004-09-01 2008-09-24 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US7666907B2 (en) * 2005-05-27 2010-02-23 Antibe Therapeutics Inc. Salts of trimebutine and N-desmethyl trimebutine
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
NZ603744A (en) * 2005-08-24 2014-06-27 Salix Pharmaceuticals Inc Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
WO2008033125A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
CA2662428A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
EP2334178A4 (de) * 2008-10-03 2012-04-11 Falk Pharma Gmbh Zusammensetzungen und verfahren zur behandlung von darmerkrankungen mit granuliertem mesalamin
WO2010042163A2 (en) 2008-10-06 2010-04-15 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
EP2488163A1 (de) 2009-10-16 2012-08-22 Ranbaxy Laboratories Limited Pharmazeutische zusammensetzung aus mesalamin mit verzögerter freisetzung
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
JP6203816B2 (ja) 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
US9763887B2 (en) 2013-03-15 2017-09-19 Allergan Pharmaceuticals International Limited Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP4636401A2 (de) 2014-12-19 2025-10-22 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
EP3370782A4 (de) 2015-11-02 2019-07-24 Pura Scents, Inc. Duftabgabe
USD809116S1 (en) 2015-11-02 2018-01-30 Pura Scents Dispenser
USD816506S1 (en) 2015-11-02 2018-05-01 Pura Scents, Inc. Vial for a scent dispenser
EP3446119A1 (de) 2016-04-18 2019-02-27 The Broad Institute Inc. Verbesserte hla-epitopvorhersage
EP3257501A1 (de) 2016-06-14 2017-12-20 Tillotts Pharma AG Aus mehreren einzeleinheiten zusammengesetzte dosierungsform mit einem kern aus individuellen kerneinheiten, die mit mukoadhäsivem material bedeckt sind, sowie einer enterischen kernbeschichtung
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
EP4158014A2 (de) 2020-05-26 2023-04-05 Dionis Therapeutics, Inc. Bibliotheken künstlicher mini-proteome aus nukleinsäuren
EP4426829A1 (de) 2021-11-01 2024-09-11 Dana-Farber Cancer Institute, Inc. Biologisch ausgewählte bibliotheken künstlicher miniproteome von nukleinsäuren

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
PH10958A (en) * 1967-08-18 1977-10-13 Abbott Lab Tablet preparation
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition
US4190716A (en) * 1978-12-20 1980-02-26 Dynapol Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
JPS57500432A (de) * 1980-03-20 1982-03-11
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap

Also Published As

Publication number Publication date
FI85216C (fi) 1992-03-25
JPS58501174A (ja) 1983-07-21
GB2123695A (en) 1984-02-08
GB2123695B (en) 1985-05-01
FI85216B (fi) 1991-12-13
EP0097651A1 (de) 1984-01-11
DK128283D0 (da) 1983-03-21
DK158931B (da) 1990-08-06
US5541170A (en) 1996-07-30
JPH0414083B2 (de) 1992-03-11
NO159696B (no) 1988-10-24
IT8248908A0 (it) 1982-07-29
ZA825384B (en) 1983-05-25
FI833099L (fi) 1983-08-31
EP0097651B1 (de) 1986-01-02
DK158931C (da) 1990-12-31
DK128283A (da) 1983-03-21
IT1149328B (it) 1986-12-03
AU8732482A (en) 1983-02-22
FI833099A0 (fi) 1983-08-31
CA1172570A (en) 1984-08-14
US5541171A (en) 1996-07-30
GB8322387D0 (en) 1983-09-21
DE3268277D1 (en) 1986-02-13
AU551173B2 (en) 1986-04-17
WO1983000435A1 (en) 1983-02-17
NO830948L (no) 1983-03-17
NO159696C (no) 1989-02-01

Similar Documents

Publication Publication Date Title
ATE17189T1 (de) 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.
KR930702963A (ko) 장질환 치료를 위한 서방성 경구 투약 형태
FI823975L (fi) Farmaceutisk flerenhetssammansaettning
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
NO980047L (no) Blanding for tildeling av et polart medikament i kolon
DK546389D0 (da) Farmaceutisk sammensaetning paa enhedsdosisform til peroral administration
Isaacs et al. Pancreatitis after rectal administration of 5-aminosalicylic acid
DE59803511D1 (de) Expandierbares gastroretentives therapie-system mit kontrollierter wirkstofffreisetzung im gastrointestinaltrakt
DZ2316A1 (fr) Micro sphères pharmaceutiques d'acide valproique pour administration orale.
IT1303753B1 (it) Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
FR2319346A1 (fr) Medicament comprenant une association d'un agent anti-inflammatoire et d'un imidazole ou d'un benzimidazole
KR880007066A (ko) 우라피딜의 약제 형태
GB1463955A (en) Compositions containing prostaglandins
Tabata et al. Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)
JPS5515458A (en) Hypotensive agent
JPS5352617A (en) Solid drug coating composition
TH31107B (th) ยาเม็ดเคลือบฟิล์มสำหรับความปลอดภัยที่ดีขึ้นสำหรับทางเดินกระเพาะลำไส้ตอนบน